Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin August Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

Construction Initiated on Cell Therapy Catapult’s £55 Million Cell and Gene Therapy Manufacturing Centre

publication date: Dec 10, 2015
 | 
author/source: Cell Therapy Catapult

Turf cut on new 7,200m2 facility

catapultThe Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official initiation of construction for its cell and gene therapy manufacturing centre. 

John Brown marked the beginning of construction at an event on the site. Marking the importance of the manufacturing centre to the international cell and gene therapy sectors, the event has been attended by a range of figures representing academic, healthcare, regulatory and industry interests across the advanced therapy sectors. 

The Cell Therapy Catapult manufacturing centre is due to be completed and opened in 2017. When completed, the venue will be spread over a 7,200m2 area. It is being built in Stevenage at the centre of a growing cluster. In addition, close proximity to international air transport links at London Heathrow airport will enable time critical transport of the cells of patients to and from the developer facility.

Innovate UKthe UK’s innovation agency, has committed £55 million to the Cell Therapy Catapult for the creation of the centre. It will directly create up to 150 specialist jobs, and many more additional roles in the cluster that grows around it. The UK government and Cell Therapy Catapult also anticipate the centre will attract considerable inward investment to the UK. Most importantly, by providing a direct solution to central challenges for the development of cellular therapies, it will speed up the developments of critically needed treatments for patients in the UK and internationally.  

“The Cell Therapy Catapult cell and gene therapy manufacturing centre will be the world’s first facility of its kind. I am very proud that it will be built in the UK,” said George Freeman, MP, UK Government Minister for Life Sciences. “The UK is at the leading edge of the cell and gene therapy industry, with a disproportionate share of both world leading scientists and new developments in the field. It will also contribute to considerable additional inward investment to the UK. This has created an advantage upon which the country has to continue to capitalise. The centre will contribute to the development of a large scale industry in the UK and the development of a cell and gene therapy cluster that will deliver both health and wealth to the UK.”

“Initiating construction on our £55 million, 7,200m2 manufacturing centre is a major milestone for the Cell Therapy Catapult,” said Keith Thompson, CEO, the Cell Therapy Catapult. “Manufacturing continues to involve significant international logistical and regulatory challenges to the development of cell therapies. The manufacturing centre will be a game changer for the UK cell therapy industry, as well as the future international availability of therapies for patients. Both UK and international companies will now be able to plan and spread costs via economies of scale for their manufacturing for clinical trials for the UK, European and global markets.” 

Innovate UK Chief Executive Ruth McKernan said “This pioneering new manufacturing facility will be a huge asset for UK life sciences businesses and will act as a magnet for inward investment, further reinforcing the UK as a global leader in cell and gene therapies.”

About the Cell Therapy Catapult

The Cell Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s eight great technologies that support UK science strengths and business capabilities.  The Cell Therapy Catapult works with Innovate UK.


more about cell therapy catapult


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners